Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy
Launched by MARSIBIONICS · Sep 19, 2022
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medical authorization to for standing, gait training and weight bearing.
- • Maximum user weight of 35 kg.
- • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm.
- • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm.
- • Hip width (between greater trochanteres) less than or equal to 35 cm.
- • Do not have an allergy to any of the ATLAS materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.
- • Ability to achieve the neutral position of the ankle, during the use of the device with or without technical aids.
- • Informed consent signed by legal guardians.
- • Confirmed diagnosis of cerebral palsy affecting the ability to walk.
- • Stable medical condition without modifications of the specific medication for the disease in the last 6 months, and other additional medication in the last month.
- • Patient in follow-up according to the normal standards recommended for his illness.
- Exclusion Criteria:
- • More than 20º of hip flessum at the time of using the exoskeleton.
- • More than 20º of knee flessum at the time of using the exoskeleton.
- • Severe skin lesion on parts of the lower extremities that are in contact with the device.
- • Scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months.
- • History of fracture without trauma. History of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months.
- • Refusal of the patient or legal guardian to include the child in the study.
- • Skin problems (diseases, allergies, sensitivity ...) that prevent the use of exoskeleton accessories on the patient's skin.
- • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
About Marsibionics
Marsibionics is an innovative biotechnology company dedicated to advancing the field of rehabilitation and mobility solutions through cutting-edge robotic technologies. Focused on developing state-of-the-art exoskeletons and assistive devices, Marsibionics aims to enhance the quality of life for individuals with mobility impairments. By integrating advanced engineering, neuroscience, and user-centered design, the company strives to create effective therapeutic tools that facilitate recovery and promote independence. Committed to rigorous clinical evaluation, Marsibionics actively sponsors clinical trials to validate the efficacy and safety of its products, ensuring they meet the highest standards of care in rehabilitation and assistive technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zaragoza, , Spain
Zaragoza, Aragón, Spain
Madrid, , Spain
Zaragoza, , Spain
Zaragoza, , Spain
Madrid, , Spain
Madrid, , Spain
Zaragoza, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials